| Number: 201103308 |
Principal Investigator: Linette, Gerald |
| Title: Mature Dendritic Vaccination Against gp100 in Patients with Advanced Melanoma |
| Description: You may be asked to participate in this study because you have been diagnosed with metastatic melanoma. Although there are treatments that can control your disease for a period of time, there are no treatments that have been shown to cure melanoma once it has spread to distant sites in the body (su...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201010741 |
Principal Investigator: Linette, Gerald |
| Title: Phase I/II study to assess the safety and activity of enhanced TCR transduced autologous T cells against cancer-testis antigens in metastatic melanoma |
| Description: The purpose of this clinical trial is to assess the effects (both good and bad) of chemotherapy and treatment with modified T cells on cancer and general health....MORE |
| ___________________________________________________________________________________________________ |
| Number: P2C 8443 |
Principal Investigator: Linette, Gerald |
| Title: Randomized Phase II Trial of Temozolomide versus Hyd-sulfate AZD6244 [NSC 748727] in Patients with Metastatic Uveal Melanoma |
| Description: The purpose of this research study is to find out if treatment with AZD6244 or temozolomide
(TMZ) can stop your melanoma from growing. AZD6244 is an experimental drug. An experimental drug is a medication that is not approved by the FDA. AZD6244 is a pill that
blocks a protein called MEK. Most uve...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209059 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: Multisite randomized controlled trial of continuing vs. discontinuing statins |
| Description: The purpose of this study is to determine if discontinuing statin medications is safe and can reduce the burden of taking numerous medications. We anticipate that people with advanced illness will have less medicine-related side effects and symptoms if statins are discontinued, better quality of lif...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107040 |
Principal Investigator: Linette, Gerald |
| Title: A Phase II Study of Sunitinib (SUTENT) in Patients with Metastatic Mucosal or Acral/Lentiginous Melanoma |
| Description: The purpose of this study is to evaluate how effective an investigational drug called SUTENT® works in treating acral lentigenous and mucosal melanoma which has spread beyond the local region.
...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102071 |
Principal Investigator: Linette, Gerald |
| Title: A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma |
| Description: In this study, we will test the effect of the drug IMCgp100 directly on tumors by injecting the drug directly into the tumor....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU E1609 |
Principal Investigator: Linette, Gerald |
| Title: A Phase III Randomized Study of Adjuvant Ipilimumab
Anti-CTLA4 Therapy Versus High-Dose Interferon a-
2b for Resected High-Risk Melanoma |
| Description: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on patients and their melanoma to find out which is better....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB N0879 |
Principal Investigator: Linette, Gerald |
| Title: A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without
Everolimus for Therapy of Metastatic Malignant Melanoma (N0879) |
| Description: There are two purposes of this research study. They are:
Find out what effects (good and bad) the combination of study drugs has on patients and their melanoma
Find out what effects the combination of study drugs has on each patient's immune system and the way their tumor grows...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201211044 |
Principal Investigator: Linette, Gerald |
| Title: A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy |
| Description: The purpose of this study is to test the effectiveness, safety, and tolerability
of an investigational drug called BMS-936558.
The effectiveness of BMS-936558 in melanoma will be determined by comparing the observed change in tumor size and the survival of participants who receive the investigati...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201211017 |
Principal Investigator: Linette, Gerald |
| Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma |
| Description: In this study we will compare Pimasertib to Dacarbazine. The primary research study goal is to compare the length of time, during and after treatment, in which patients can live without their disease getting worse. Additional purposes of the study are to find out about the side effects of Pimaserti...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209116 |
Principal Investigator: Linette, Gerald |
| Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib versus Vemurafenib Plus Gdc-0973 in Previously Untreated BRAFV600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma |
| Description: The purpose of this study is to compare the effects, good and/or bad, of GDC-0973 and vemurafenib with vemurafenib alone on patients and their melanoma, to find out which is better....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201206092 |
Principal Investigator: Linette, Gerald |
| Title: A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma |
| Description: The main purpose of this study is to evaluate the safety and tolerability of tumor injections of INXN-2001 given in combination with different doses of INXN-1001 for patients with unresectable stage III or IV melanoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205056 |
Principal Investigator: Linette, Gerald |
| Title: A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence |
| Description: The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients have undergone surgery....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201204076 |
Principal Investigator: Linette, Gerald |
| Title: An Open-Label, Multicenter, Phase II Study of Continuous Oral Vemurafenib in Patients with Locally Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations other than V600E |
| Description: The purpose of this study is to assess the potential side effects and effectiveness of vemurafenib as an investigational drug for the treatment of metastatic melanoma in patients with other than BRAF V600E mutations....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107023 |
Principal Investigator: Linette, Gerald |
| Title: A Phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma |
| Description: The purpose of this clinical research study is to find out if the drug LDE225 is safe and has beneficial effects in people who have basal cell carcinoma (skin cancer),...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201211040 |
Principal Investigator: Linette, Gerald |
| Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence |
| Description: The purpose of this study is to find out whether vemurafenib can help prevent or delay the return of melanoma that is at a high risk of returning (Stage IIC, IIIA, IIIB or IIIC) after it has been removed surgically.
The study will also assess whether the drug causes side effects in patients....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109292 |
Principal Investigator: Cornelius, Lynn |
| Title: Tissue Acquisition for Analysis of Genetic Factors in Melanoma and Other Skin Cancers |
| ___________________________________________________________________________________________________ |
| Number: 201105020 |
Principal Investigator: Anadkat, Milan |
| Title: Retrospective and Prospective Data Collection and Analysis of Cutaneous Chemotherapy REACTions at Washington University |
| ___________________________________________________________________________________________________ |